This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


Worse overall survival seen for adults with leukemia with CNS involvement

Worse overall survival seen for adults with leukemia with CNS involvement

For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the February issue of Leukemia Research.

Hannah Goulart, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a and meta-analysis to characterize in patients with AML with CNS involvement. Survival outcomes and response rates were examined from clinical studies of patients with AML stratified by CNS involvement. The meta-analysis included 12 studies.

The researchers found that overall survival was worse for patients with CNS involvement versus those without CNS involvement. In three studies examining complete remission, there was no significant difference observed for patients with versus without CNS involvement. Similarly, no significant difference was seen between CNS-positive versus CNS-negative patients in terms of disease-free survival or relapse-free survival outcomes based on five studies that included this outcome.

"We were able to identify through a that patients with AML and evidence of CNS involvement have inferior survival when compared to patients without CNS disease," the authors write.

Two authors disclosed ties to the pharmaceutical and biopharmaceutical industries.

More information: Hannah Goulart et al, Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement, Leukemia Research (2024). DOI: 10.1016/j.leukres.2024.107452

Copyright © 2024 HealthDay. All rights reserved.

Citation: Worse overall survival seen for adults with leukemia with CNS involvement (2024, February 21) retrieved 21 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Outcomes similar for therapy-related, de novo MDS after haplo-HSCT


Feedback to editors